Nanox Files 2023 Annual Report on Form 20-F
Nanox Files 2023 Annual Report on Form 20-F
PETACH TIKVA, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission ("SEC") on April 22, 2024. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at https://www.sec.gov/ and on the Company's website at https://www.nanox.vision/ under "Financials" in the Investors section.
以色列PETACH TIKVA，2024年4月22日（GLOBE NEWSWIRE）——创新医学成像技术公司NANO-X IMAGING LTD（“Nanox” 或 “公司”，纳斯达克股票代码：NNOX）今天宣布，它已于2024年4月22日向美国证券交易委员会（“SEC”）提交了截至2023年12月31日财年的20-F表年度报告。20-F表年度报告包含公司经审计的合并财务报表，可在美国证券交易委员会的网站上访问 https://www.sec.gov/ 并在公司的网站上 https://www.nanox.vision/ 在 “投资者” 部分的 “财务” 下。
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, at IR@nanox.vision.
公司将应要求免费向股东提供包含经审计的合并财务报表的年度报告的纸质副本。申请应发送至投资者关系部，电子邮件地址为 IR@nanox.vision。
About Nanox
关于 Nanox
Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox's vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease (Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox's subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox's products and services create a worldwide, innovative, and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision.
Nanox（纳斯达克股票代码：NNOX）专注于应用其专有的医学成像技术和解决方案，使诊断药物在全球范围内更容易获得和负担得起。Nanox的愿景是增加常规医学成像技术和流程的可及性，降低成本并提高其效率，以改善早期发现和治疗，Nanox认为这是帮助人们获得更好的健康结果并最终挽救生命的关键。Nanox生态系统包括Nanox.arc——一种具有成本效益且用户友好的多源数字断层合成系统；一套基于人工智能的算法，可增强常规CT成像的读数，以突出通常与慢性病相关的早期症状（Nanox.AI）；基于云的基础架构（nanox.Cloud）；以及通过Nanox的子公司USARAD Holdings Inc.提供的专有去中心化市场，为放射学和心脏病学专家提供远程访问；以及全面的远程放射学服务平台（Nanox.Marketplace）。Nanox 的产品和服务共同创造了一个全球性、创新的全面解决方案，将从扫描到诊断的医学成像解决方案连接起来。欲了解更多信息，请访问 www.nanox.vision。
Contacts
联系人
Media Contact:
Ben Shannon
ICR Westwicke
NanoxPR@icrinc.com
媒体联系人：
本·香农
ICR Westwicke
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Westwicke
mike.cavanaugh@westwicke.com
投资者联系人：
迈克·卡瓦诺
ICR Westwicke
mike.cavanaugh@westwicke.com